https://www.actasdermo.org/es-translated-article-use-anifrolumab-in-articulo-S0001731024007658
[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus...
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently
systemic lupus erythematosustranslatedarticleuseanifrolumab
https://medicament.saniscope.fr/substance/anifrolumab/
ANIFROLUMAB : médicaments, notices et sources officielles — Saniscope Médicaments
Liste des médicaments contenant ANIFROLUMAB, formes disponibles, ruptures importées et sources officielles.
anifrolumabnoticessourcesofficielles
https://www.jrheum.org/content/51/11/1096.tab-references
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study | The...
Objective To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE). Methods The present study is a...
systemic lupus erythematosusreal worldmulticenter studyanifrolumabrefractory
https://www.nordicbioscience.com/publication/suppression-of-t-cell-activation-and-collagen-accumulation-by-an-anti-ifnar1-mab-anifrolumab-in-adult-patients-with-systemic-sclerosis/
Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in...
Aug 21, 2026 - Abstract Type I IFNs are implicated in the pathophysiology of systemic sclerosis (SSc). Recently, a Phase I open-label trial was conducted with an anti-IFNAR1...
t cell activationsuppressioncollagenaccumulationanti